Sonidegib治疗晚期基底细胞癌:BOLT研究42个月最终分析
BOLT研究42个月最终分析评估Sonidegib治疗晚期基底细胞癌的长期疗效与安全性。未出现新安全性信号,支持其作为长期治疗选择。
要点
- Sonidegib 200mg每日一次治疗局部晚期基底细胞癌客观缓解率达56%。
- 转移性基底细胞癌客观缓解率较低,200mg组为8%。
- 42个月随访未发现新的安全性问题,疗效持续。
核心结论
- Sonidegib在晚期基底细胞癌中显示出持续疗效和可控的安全性,支持其作为长期治疗选择。
研究设计与样本
- II期随机双盲BOLT研究最终42个月分析,成人无既往Hedgehog通路抑制剂治疗史,按1:2随机接受Sonidegib 200mg或800mg每日一次。
- 共纳入230例患者,200mg组79例,800mg组151例。
主要发现
- 42个月截止时,200mg组8%、800mg组3.3%的患者仍在治疗。
临床怎么用
- Sonidegib可作为局部晚期和转移性基底细胞癌的长期治疗选项。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Basal cell carcinomas (BCCs) exhibit aberrant activation of the hedgehog pathway. Sonidegib is a hedgehog pathway inhibitor approved for the treatment of locally advanced BCC (laBCC) and metastatic BCC (mBCC) based on primary results of the BOLT study [Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment]. OBJECTIVES: This is the final 42-month analysis of the BOLT study, evaluating the efficacy and safety of sonidegib. METHODS: Adults with no prior hedgehog pathway inhibitor therapy were randomized in a 1 : 2 ratio to sonidegib 200 mg or 800 mg once daily. Treatment continued for up to 42 months or until disease progression, unacceptable toxicity, death, study termination or withdrawal of consent. The primary efficacy end point was the objective response rate (ORR) by central review, assessed at baseline; weeks 5, 9 and 17; then subsequently every 8 or 12 weeks during years 1 or 2, respectively. Safety end points included adverse event monitoring and reporting. RESULTS: The study enrolled 230 patients, 79 and 151 in the 200-mg and 800-mg groups, respectively, of whom 8% and 3.3% remained on treatment by the 42-month cutoff, respectively. The ORRs by central review were 56% [95% confidence interval (CI) 43-68] for laBCC and 8% (95% CI 0·2-36) for mBCC in the 200-mg group and 46·1% (95% CI 37·2-55·1) for laBCC and 17% (95% CI 5-39) for mBCC in the 800-mg group. No new safety concerns emerged. CONCLUSIONS: Sonidegib demonstrated sustained efficacy and a manageable safety profile. The final BOLT results support sonidegib as a viable treatment option for laBCC and mBCC. What's already known about this topic? Basal cell carcinoma (BCC) is usually treatable with surgery or radiation therapy, but there are limited treatment options for patients with advanced BCC. Sonidegib, a hedgehog pathway inhibitor approved for the treatment of advanced BCC, demonstrated clinically relevant efficacy and manageable safety in prior analyses of the phase II randomized, double-blind BOLT study [Basal Cell Carcinoma Outcomes with LDE225 (sonidegib) Treatment]. What does this study add? This final 42-month analysis of BOLT is the longest follow-up available for a hedgehog pathway inhibitor. Clinically relevant efficacy results were sustained from prior analyses, with objective response rates by central review of the approved 200-mg daily dose of 56% in locally advanced BCC and 8% in metastatic BCC. No new safety concerns were raised. The results confirmed sonidegib as a viable long-term treatment option for patients with advanced BCC.
引用
- Dummer R, Guminksi A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study. Br J Dermatol. 2019. PMID: 31545507. doi:10.1111/bjd.18552
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。